Uterine fibroids are a common finding in infertility patients. Impaired implantation and decidualization have been proposed to contribute to compromised fertility. Data are limited on the endometrial transcriptome from subjects with uterine fibroids, as well as endometrial receptivity and decidualization potential of endometrial stromal fibroblasts (eSF) from women with fibroids. Our objective was to investigate the endometrial transcriptome of women with noncavity-distorting intramural fibroids and compare them to control subjects with no uterine pathology throughout the menstrual cycle. We also evaluated endometrial receptivity gene expression and basic endometrial functions such as decidualization, proliferation, and apoptosis in women with fibroid uterus. Results showed that large numbers of transcripts were significantly dysregulated throughout the menstrual cycle in fibroid subjects compared to controls. However, there were essentially no differences in the expression of receptivity markers at the tissue level, as well as decidualization markers in tissue and eSF in subjects with fibroids compared to controls. However, eSF from women with a fibroid uterus exhibited decreased proliferation potential and increased apoptosis upon decidualization. These data indicate preserved implantation and decidualization potential despite observed gene expression changes in endometrium from women with noncavity-distorting fibroids compared to controls. How this phenomenon and altered proliferation/apoptosis may contribute to impairment of endometrial function in subfertile patients warrants further investigation.
Introduction
Uterine leiomyoma (also known as leiomyomata or fibroids, referred hereafter as uterine fibroids) are the most common benign pelvic organ tumors in reproductive age women [1] . They can be found incidentally during imaging or can be symptomatic causing abnormal uterine bleeding, pelvic pressure, pelvic pain, and/or reproductive 564 C The Authors 2017. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com dysfunction (e.g. poor pregnancy outcomes including miscarriage and preterm labor), depending on size and location within the uterus [2] . However, much of the data on the potential impact of uterine fibroids on fertility are not clear, and both clinical and experimental data are conflicting on whether endometrial receptivity is impaired in women with uterine fibroids. Uterine fibroids are classified as subserosal (under the peritoneal serosa (outer surface of the uterus) with some or no extension into the myometrial muscle layer), intramural (within the muscle layer and not extending beyond), and submucosal (abutting or protruding into the uterine cavity and distorting the endometrium) according to their location in the uterus [3] . The detrimental effect of submucosal and large cavity distending fibroids on reproductive outcomes is well established and guides clinical management, accordingly [4, 5] . With regard to fibroids that do not distort the cavity, the data are less clear and support reproductive compromise as well as no effect on reproduction. For example, Oliveira et al. showed no correlation between location and size of intramural uterine fibroids on in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) outcomes [6] . However, intramural fibroids >4 cm were associated with lower pregnancy rates compared to intramural fibroids ≤4.0 cm, but similar delivery rates, compared to control women with no fibroids, while subserosal fibroids had no effect on treatment outcome [6] . Klatsky et al. showed no difference in implantation and clinical pregnancy rates in oocyte recipients with noncavity-distorting fibroids (subserosal or intramural, regardless of size and location) [7] . A systematic review (of seven studies) showed no difference in fertility outcomes of infertile women with subserosal fibroids compared to infertile women without fibroids [5] . In contrast, patients with intramural fibroids had decreased implantation rates and increased pregnancy loss compared to controls; however, it is unclear from the studies if and how the endometrial cavity prior to treatment was evaluated, thus providing insufficient evidence to support intervention in women with intramural fibroids [5] . Prospective and retrospective analyses from one center revealed decreased cumulative and ongoing pregnancy rates and live birth rates in IVF/ICSI cycles in subjects with ≤5 cm intramural fibroids compared to matched controls without fibroids [8, 9] . A meta-analysis of 19 studies/6087 cycles demonstrated a significant decrease in live birth rate (RR = 0.79, 95% CI: 0.70-0.88, P < 0.0001) and clinical pregnancy rate (RR = 0.85, 95% CI: 0.77-0.94, P = 0.002) with no difference in implantation and miscarriage rates in noncavity-distorting intramural fibroids, compared to no fibroids (P = 0.11 and P = 0.07, respectively) [10] . A recent retrospective study showed lower endometrial thickness (8.33 ± 1.8 vs 8.73 ± 2.03 mm) and increased early miscarriage rates in donor egg recipients with fibroids not impinging uterine cavity, with live birth and stillborn rates comparable to controls and no implantation rate or preterm delivery rate data reported [11] . Thus, there are conflicting data on the effect of noncavity-distorting uterine fibroids of varying sizes on fertility, which makes patient counseling and management challenging.
From a molecular perspective, Horcajadas et al. performed microarray analysis of mid-secretory endometrium from women with uterine fibroids (various size and number of fibroids) compared to healthy controls and concluded that overall, intramural fibroids that do not distort the endometrial cavity have no effect on endometrial receptivity based on minimal differences in the comparative expression of the established 25 implantation-related genes that were analyzed [12] . In addition, the study reported no difference in term pregnancy rates and no correlation between implantation and miscarriage rates with number and size of fibroids [12] . In the same study, histological evaluation of mid-secretory endometrium from patients with fibroids, according to the Noyes criteria [13] , showed that the presence of large (>5 cm), but not small (≤5 cm), intramural fibroids induced <2 day delay in the development of receptive endometrium [12] . This, however, was thought to be clinically insignificant as a delay of more than 3 days is associated with impaired implantation [14] .
Alternative observations however suggest that uterine fibroids do compromise implantation and fertility. For example, decreased HOXA10 expression in microdissected stromal fibroblasts from mid-secretory endometrium of infertile patients with noncavitydistorting intramural uterine fibroids was suggested to signify decreased endometrial receptivity [15] . Furthermore, Rackow and Taylor showed decreased expression of the implantation-related genes HOXA10, HOXA11, and KLF9 in the presence of submucosal fibroids, not only in the area overlying the fibroid, but throughout the entire endometrium, with no significant effect of intramural fibroids on the expression of the above genes [16] . However, no difference was found for LIF (a marker of the implantation window) mRNA expression between groups [16] .
Given that current information is inconclusive, we performed the first global gene expression analysis at various times in the menstrual cycle of endometrium from women with noncavity-distorting uterine fibroids, compared to carefully selected controls without uterine or pelvic pathology, with a focus on processes relevant to implantation. We further analyzed decidualization of the endometrial stromal fibroblasts (eSFs) in these groups, due to their relevance to pregnancy outcomes [17, 18] .
Materials and methods
Participating subjects, tissue sampling, and experimental design Endometrial tissue samples from different phases of the menstrual cycle were obtained through the UCSF/NIH Human Endometrial Tissue and DNA Bank under an approved protocol through the UCSF Committee on Human Research after written informed consent. Samples were selected from women with no uterine or pelvic pathology in the proliferative phase (PE, n = 20), early secretory phase (ESE, n = 6), and mid-secretory phase (MSE, n = 8), and with noncavity-distorting intramural fibroids (no submucosal component, as per operative report and/or pathology results): PE (n = 7), ESE (n = 3), and MSE (n = 4). The majority of the control subjects had proven fertility or were healthy volunteers without any gynecologic symptoms and most had pelvic ultrasound as part of preoperative or other evaluation, with no evidence of uterine fibroids.
Biopsy samples from control subjects were obtained using a Pipelle catheter (Cooper Surgical, Trumbull, CT) during laparoscopy or in the office setting ( Table 1) . As control subjects did not have symptoms of abnormal uterine bleeding and were not undergoing IVF/ICSI, they did not have uterine cavity visualization by saline infusion sonography, which is commonly performed for these indications and is not part of the research protocol. However, most subjects had pelvic ultrasounds that revealed no sonographic evidence of cavity abnormalities and had no symptoms to suggest such. All tissues from subjects with fibroids were obtained from hysterectomy specimens by curetting the endometrial functionalis layer. Note we have previously shown that microarray analyses are not affected by sampling technique (curetting the functionalis or obtaining tissue by Pipelle biopsy [19] ). The number of fibroids varied from one to n/a Cell culture, Q-PCR, morphology Healthy volunteer 37 Unknown PE = proliferative endometrium, ESE = early secretory endometrium, MSE = mid-secretory endometrium, LSE = late secretory endometrium, Q-PCR = quantitative polymerase chain reaction, n/a = not applicable.
"multiple" (exact number not recorded) and sizes varied from 0.5 to 7 cm for intramural fibroids, and up to 11 cm for subserosal fibroids. These samples were previously used for microarray analysis by Tamaresis et al. [20] , and the raw data files were extracted and analyzed for the current study, as described below. Menstrual cycle phase was assigned by a combination of endometrial histology, reviewed by two pathologists, confirmed by serum estradiol (E 2 ) and progesterone (P 4 ) levels, and corroborated by two independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis [20] .
Endometrial SFs were isolated and cultured from fresh endometrial biopsies obtained from women with and without intramural fibroids (n = 14 and n = 12, respectively) for subsequent cell culture experiments (see Table 1 for subject characteristics and cell usage in different experiments).
Microarray gene expression data analysis
The data generated by the Affymetrix GeneChip Operating Software analysis of the scanned array images previously published [20] were imported into GeneSpring version 11.02 (Agilent Technologies Inc., Santa Clara, CA) for analysis as previously described [21, 22] . The resulting gene lists from each pairwise comparison included only the genes that evidenced a fold change of 2.0 or higher and a pvalue less than 0.05 by a one-way ANOVA parametric test and a Benjamini-Hochberg multiple testing correction for false discovery rate, as described [23] . Unsupervised principal component analysis (PCA) algorithm was applied to all samples, using all 54,675 probe sets on the Affymetrix HU133 Plus 2.0 array, and hierarchical cluster (HC) analysis was conducted using only differentially expressed genes from all samples and among all experimental conditions to evaluate for similar gene expression patterns and underlying cluster structures, as described [21, 23, 24] . The generated heatmap graphically depicts the measured intensity values of the genes and the dendrogram illustrates relationships between the specimens. All raw data files used in this study are stored at the NCBI Gene Expression Omnibus database with the accession number GSE51981 [20] . Biological pathway analysis was carried out using Ingenuity Pathway Analysis (Qiagen, Redwood City, CA), into which gene symbols with fold changes of regulated genes were exported to identify the activation states of biological pathways, networks, and cellular functions based on the differential gene expression analysis as described [21, 22] .
Validation of microarray data by quantitative RT-PCR
A total of 28 cDNAs of samples from women with no uterine/pelvic pathology (PE, n = 10, ESE, n = 3, and MSE, n = 5) and with intramural fibroids (PE, n = 4, ESE, n = 3, and MSE, n = 3) were assayed in duplicate by q-RT-PCR using the Fluidigm Dynamic Array Integrated Fluidic Circuits and the BioMark HD system (www.fluidigm.com/biomark-system.html), as previously described [20, 21] . Briefly, 1 μg of stored mRNA from the earlier study by Tamaresis et al. [20] (RIN > 7) was converted to cDNA using the iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, USA). The cDNA was then pre-amplified to generate a pool of target genes using Taq-Man Pre-Amp master mix (Applied Biosystems, Foster City, CA), 100 ng cDNA, and 500 nM for each primer pair. Samples were then treated with exonuclease (Exonuclease I; New England BioLabs, Ipswich, MA). Using previously generated optimal dilution curves, samples were diluted 1:5 in a Tris-ethylenediaminetetraacetic acid dilution buffer (TEKnova, Hollister, CA). Q-RT-PCR was performed using SsoFast Evagreen supermix with low ROX binding dye (Bio-Rad Laboratories, Hercules, CA) and a primer concentration of 5 μM. Primers were designed by Fluidigm. Data were processed by user-detected threshold settings and linear baseline correction using Biomark real-time PCR Analysis Software (version 3.0.4). Melt curves were assessed using the melting temperature threshold. The YWHAZ housekeeping gene was used as a normalizer [25, 26] . The comparative ( ) Ct method was used to measure relative gene expression [27] .
Endometrial stromal fibroblast isolation and culture
Isolated and cultured eSFs from women with and without fibroids (n = 14 and n = 12 respectively) were used for decidualization, q-RT-PCR, proliferation WST-1, BrdU DNA incorporation, and TUNEL apoptosis assays (see below). Fresh endometrial biopsies were digested with the use of collagenase as described previously [28] . Human eSFs were separated from epithelium based on size and plated with the use of DMEM/MCDB-105 medium containing 10% charcoal-stripped fetal bovine serum (FBS), insulin (5 μg/mL), gentamicin, penicillin, and streptomycin, as described previously [22] . At passage 2, cells were cultured to near confluence in the same medium, followed by changing to low serum medium (2% FBS) and cultured for 24 h before the onset of treatment. All cell culture experiments were conducted with the use of second to fourth cell passages; cell purity (99% stromal fibroblasts) was determined by means of immunostaining with cytokeratin, vimentin, and CD45 antibodies, as described previously [28] .
Decidualization of human endometrial stromal fibroblasts
Duplicate cultures of human eSF were treated with 0.5 mM of 8-bromo-cyclic adenosine monophosphate (cAMP) for 96 h or with estradiol (E 2 , 10 nmol/L) alone or E 2 (10 nmol/L) plus progesterone (P 4 , 1 μmol/L) (E 2 P 4 ) for 14 days or vehicle, as described previously in detail [22, 29] . 8-Bromo-cAMP and steroid hormones were obtained from Sigma-Aldrich. Time "zero" (t = 0) control subjects were collected before initiation of treatment, after 24 h culture in low serum medium, as described above. Cells lysed in RLT lysis buffer (Qiagen) containing 0.1% β-mercaptoethanol and culture media were collected after 96 h of incubation (cAMP-treated samples) or 14 days (E 2 P 4 -treated samples). Endometrial SF decidualization was assessed by insulin growth factor-binding protein 1 (IGFBP1) and prolactin (PRL) q-RT-PCR and ELISA (see below).
Enzyme-linked immunosorbent assay
IGFBP1 and PRL proteins in the culture media were measured to assess the decidualization status of eSF with the use of ELISA, according to the manufacturers' instructions (Alpha Diagnostic International, San Antonio, TX and Beckman Coulter, Indianapolis IN, respectively), and as described previously in details [22, 29] .
RNA isolation and real-time RT-PCR
Total RNA was purified using Qiagen RNeasy Plus Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions, and quantified by spectroscopy. The purity was analyzed by the 260/280 absorbance ratio, and RNA integrity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). For quantitative RT-PCR analysis, 1 μg of RNA was converted to cDNA using the iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, USA). The real-time RT-PCR reaction was carried out for 40 cycles. The RPL19 housekeeping gene was used for normalization.
TUNEL apoptosis assay
Endometrial SFs (n = 3 in each group) were cultured in duplicate on eight-well chamber slides and treated with or without 8-bromocAMP for 96 h. Thereafter, cells were washed with phosphatebuffered saline (PBS) and fixed with 3% paraformaldehyde for 20 min at room temperature, then washed again, permeabilized with methanol for 20 min at room temperature, and subsequently washed with PBS. Slides were incubated with TdT (terminal deoxynucleotidyl transferase)-mediated dUDP nick-end labelling (TUNEL) solution (TdT and digoxigenin-dUTP; Roche Diagnostics) in a humidified chamber at 37
• C for 1 h. Positive control cells were incubated with 6 μmol/l camptothecin for 12 h before fixation, and negative controls were run on each slide. Color development was performed by incubating the chamber slides with Fast Red substrate solution for 10 min. Thereafter slides were rinsed with PBS and mounted with 4,6-diamidino-2-phenylindole (nuclear staining). 
Bromodeoxyuridine incorporation assay
Endometrial SFs from women with and without fibroids (n = 3 in each group, same samples as in TUNEL assay, see Table 1 ) before and after decidualization with cAMP for 96 h were subjected to a bromodeoxyuridine (BrdU) assay (Roche Diagnostics, Mannheim, Germany). Cells were plated in triplicate at 5 × 10 4 cells/well in 96-well plates and serum starved for 24 h before being incubated with or without 8-bromo-cAMP and, in the last 18 h of cAMP exposure, incubated with BrdU. Cell proliferation was measured by colorimetric absorbance of BrdU, according to the manufacturer's instructions, using a 96-well plate reader at 450 nm wavelength (Bio-Rad Laboratories).
Proliferation WST-1 assay
The WST-1 assay was used to assess metabolic activity of eSF. Cells were seeded at a density of 5 × 10 4 cells/well in 96-well plates in triplicates and cultured overnight (n = 5 from women with and without fibroids). After media change, the cells were incubated for up to 5 days, for daily treatment and harvesting. Ten microliters of WST-1 reagent (Roche Diagnostics, Laval, Quebec, Canada) was added to each well and incubated for another 4 h at 37
• C (incubation time verified by previous preliminary experiments). The absorbance was determined using a microplate reader at a test wavelength of 450 nm and reference wavelength of 650 nm (Bio-Rad Laboratories).
Cell morphology assessment
Cell morphology was routinely assessed every other day at media change, with inverted phase-contrast light microscopy (n = 13 and n = 11 from subjects with and without fibroids, respectively). The images were obtained at initial confluency and prior to cell harvesting after decidualization with E 2 P 4 for 14 days or cAMP for 96 h. Decidualized eSF cultures were classified based on cell shape as decidualized (spindle-like) or nondecidualized (polygonal/cobblestone).
Statistical evaluation
Statistical analysis for the ELISA, BrdU proliferation assay, and TUNEL assay data was performed using a two-tailed type-3 Student t-test. WST-1 and q-RT-PCR results were analyzed using one-way ANOVA. Statistical significance was determined at P ≤ 0.05.
Results

Global gene expression in endometrium from subjects with versus without noncavity-distorting fibroids
PCA of all genes showed that overall samples from subjects with intramural fibroids uteri clustered separately from control subjects, particularly proliferative (PE) and mid-secretory (MSE) phase fibroid samples cluster separately from controls ( Figure 1A ). This was confirmed with unsupervised HC analysis of differentially expressed genes in each study group, where the fibroid and control subjects clustered separately by disease rather than cycle phase (Figure 1B) . These results suggest that at the global transcriptome level, endometrium from subjects with fibroid uteri is different from control subjects with no uterine pathology, similar to reports on adenomyosis and endometriosis [30, 31] .
Comparison of endometrial samples from women with intramural noncavity-distorting fibroids with controls in the PE samples revealed 4675 differentially regulated genes (P < 0.05, FC ≥ 2), with 1949 upregulated and 2726 downregulated genes ( Figure 1C ; Supplemental Table S1 ). Comparison of differentially regulated genes in the ESE samples discovered 2231 significantly differentially expressed genes between disease and control groups with 660 genes being upregulated and 1571 downregulated ( Figure 1C ; Supplemental Table S2 ). And finally, the comparison of the MSE transcriptomes from women with intramural noncavity-distorting fibroids with controls showed 2441 genes being dysregulated, with 1864 genes upregulated and 1295 genes downregulated ( Figure 1C ; Supplemental Table S3 ). Of note, while there were large numbers of genes specific to different cycle phases as expected, 157 genes were significantly upregulated and 373 were significantly downregulated common genes throughout all cycle phases.
Similar to our recent data in endometriosis [20] , we found cycle-independent upregulation of several genes, such as JUN (and its isoforms), FOS, and its homolog FOSB, (3.3-, 2.4-, 2.9-fold, 17.7-, 10.9-, 26.1-fold, and 20.6-, 18.7-, 16.4-fold respectively across the various cycle phases, see Supplemental tables), protooncogene/transcription factors induced by cytokines, growth factors, and estradiol that modulate expression of genes regulating cell proliferation, differentiation, survival, and angiogenesis [32] . This independence of hormonal influence in the above genes was consistent with previous reports [33] .
Microarray validation by real-time RT-PCR
Some of the highly upregulated or downregulated genes as well as some hormone regulated genes known to play an important role in endometrial physiology were selected for validation using realtime RT Comparative analysis of canonical pathways in endometrium from subjects with versus without noncavity-distorting fibroids Pathway analysis of significantly regulated gene profiles revealed several associated network functions identified as different between control subjects and those with noncavity-distorting fibroids in PE, ESE, and MSE, with several genes involved in more than one network/pathway. Canonical pathways include both signaling and metabolic pathways, and several of them were significantly (P < 0.05, Z-score > 1.5) affected when comparing endometrium from women with versus without noncavity-distorting fibroids (Supplemental Table S4 ). The largest number of dysregulated (activated and inhibited) pathways between control and study groups was observed in PE, in parallel to also the largest number of dysregulated genes being in that comparison group, and were related to TGF-β and TNFR1 signaling and cell cycle among the others. ESE demonstrated differences in growth factor and chemokine signaling and in immune pathways, while MSE displayed the least differences in activated/inactivated pathways, in line with the overall findings in the current study (Supplemental Table S4 ).
Endometrial receptivity and decidualization are not significantly affected in endometrium from women with noncavity-distorting fibroids
Comparison of the differentially expressed genes in the MSE phase (Supplemental Table S3 ) with the 238 Endometrial Receptivity Array (ERA) genes (clinically used set of genes to assess endometrial receptivity, [34] ) showed that only eight genes were upregulated (IL2RB, C11orf8c, CDC20c, CDAc, NKG7, CTSW, CFDc, RPRMc) in midsecretory endometrium from women with noncavity-distorting intramural fibroids beyond the ERA threefold threshold compared to controls. We then turned our attention to the process of endometrial stromal cell decidualization in subjects with fibroid uterus, which has been significantly underexplored, compared to, for example, the extensively documented impaired decidualization in the setting of endometriosis [22, 29, 35] . When evaluating decidualization markers, q-RT-PCR and ELISA results showed an increased expression of IGFBP1 mRNA, but not prolactin, in fibroid versus control group at the tissue level (as above), but no significant difference was found in cultured endometrial stromal cells on mRNA or protein levels (Figure 2A-C) . No difference was seen in SST, GPX3, EBAF, FOXO1A or HSD17B1, HSD17B2, and aromatase mRNA between fibroid and control group on tissue levels or in eSF decidualized with either E 2 P 4 or cAMP (Figure 2A and B) . PRB mRNA, but not ESR1, ESR2, or PRA, was significantly downregulated in fibroid versus control group eSF when decidualized with E 2 P 4 ( Figure 2A) . HOXA10 mRNA showed a small but statistically significant (P < 0.05) upregulation in eSF in fibroid versus control group upon decidualization with cAMP ( Figure 2B) .
Morphology of eSF from subjects with noncavity-distorting intramural fibroids was assessed with light microscopy before and after decidualization with E 2 P 4 and/or cAMP. No significant difference upon decidualization was seen between the two groups (data not shown).
Proliferation and apoptosis
Proliferation of eSF from subjects with noncavity-distorting fibroids was evaluated with WST-1 and BrdU assays. At baseline, there was no difference in eSF proliferation in WST-1 assay in fibroid versus control group, with statistically significant decrease noted from day 3 in the fibroid group (P < 0.03) ( Figure 3A) . BrdU incorporation was significantly decreased upon decidualization with cAMP in both fibroid and control groups (P < 0.02), as expected, and no difference in BrdU incorporation was observed between nondecidualized (A) (B) (C) and decidualized eSF from fibroid versus control group (P > 0.1) ( Figure 3B ). Expression of BAX and BCL2 apoptosis-related genes and Cyclin D1 (CCND1) and CDKN1A (p21) cell-cycle genes was not different under any condition (P > 0.1) (data not shown). However, the number of apoptotic cells in the TUNEL assay increased upon decidualization with cAMP in both groups (P < 0.006), but was significantly higher in fibroid versus control decidualized eSF (P = 0.0005) ( Figure 3C ).
Discussion
To our knowledge, this is the first study presenting the comparative evaluation of the endometrial transcriptome of women with intramural noncavity-distorting fibroids compared to healthy controls with no uterine pathology. This study is also the first to address the decidualization and growth potential of eSF from women with such fibroids.
The clinical results of managing infertile women with this very common uterine pathology are abundant, albeit still controversial regarding the clinical significance for fertility, as discussed above in the Introduction. Remarkably, the latest comprehensive secondary analysis of 900 couples with unexplained infertility (109/900 with at least one documented fibroid and a normal uterine cavity) who participated in the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) clinical trial demonstrated no differences in conception and live birth rates in women with noncavitydistorting fibroids and those without [36] , supporting current counseling strategy and the data presented herein. Despite the large number of differentially expressed genes between different menstrual cycle phases in the two groups in the study, there was no evidence from the whole tissue endometrial transcriptome that key processes believed to be responsible for successful implantation (e.g. Downloaded from https://academic.oup.com/biolreprod/article-abstract/97/4/564/4097576 by OUP site access user on 08 October 2018 receptivity and decidualization), proliferation, and apoptosis of the eSFs, were altered considerably in subjects with noncavity-distorting uterine fibroids. It is unknown, however, if these differentially expressed genes could account for any adverse pregnancy outcomes and/or if analysis of individual cell populations may reveal other cell-specific endometrial alterations.
Analysis of the endometrial transcriptome from women with noncavity-distorting fibroids throughout the different menstrual cycle phases provides information about the differentially expressed genes under the specific hormonal effects existing in PE, ESE, and MSE. Consequently, analysis of dysregulated genes and signaling pathways that are common in all three cycle phases provides information about the abnormalities that are hormone-independent and are intrinsic to the presence of uterine fibroids. The 530 differentially expressed endometrial genes in the fibroid versus control group and independent of cycle phase would support intrinsic, underlying alterations in the endometrium of uteri with noncavity-distorting fibroids.
Estrogen has been considered a major promoter of fibroid growth [37, 38] , and increased levels of aromatase and 17b-hydroxysteroid dehydrogenase enzymes (HSD17B1 and 2) have been reported in fibroid (myometrial) cells [37, [39] [40] [41] [42] [43] , with increased local production of estradiol by leiomyoma cells, and increased expression of both estrogen receptors in the fibroid tissue compared to normal myometrium [44, 45] . In our study of the endometrial uterine cells, we did not observe any difference in aromatase, 17bHSD 1 and 2, as well as estrogen receptor expression on the mRNA level. We have shown in our earlier study, however, that endometrial stromal cells from subjects with fibroid uterus (unspecified location) were able to produce low levels of aromatase, but the estradiol level in the culture media from these cells was undetectable [28] .
There is growing evidence that progesterone plays a critical role in uterine fibroid growth [37, 46] likely by mediating the estrogen effect [47] . Progesterone receptor expression has also been reportedly elevated in fibroid myometrial cells compared to normal myometrium [44, 48, 49] , and its transcript was increased in endometrium of women with abnormal uterine bleeding due to fibroids or other causes compared to controls [50] . In the current study, endometrial PGR mRNA was downregulated over twofold in MSE and PE in uteri with noncavity-distorting fibroids versus controls. As mentioned above, based on abundant clinical and experimental evidence, progesterone is accepted as a potent mitogen for fibroids (review [51] ). Elegant experiments by Ishikawa et al. using a human fibroid xenograft under the subrenal capsule of SCID mice showed that the growth and proliferation of the xenografts depended on the combination of estradiol and progesterone, but not either one of them alone [47] , suggesting a permissive role of estrogen for progesterone action on fibroid tissue. This being said, comparable data on endometrium from women with fibroids are wanting, and therefore the significance of our findings needs further validation.
Endometrial receptivity genes not affected in subjects with noncavity-distorting fibroids Among the few currently available molecular tests for endometrial receptivity, ERA is the most comprehensive and commonly used and the one that helps to guide clinical management in specific circumstances [34, 52] . Therefore, we compared the endometrial gene expression signature of endometrium from subjects with noncavitydistorting fibroids to the genes on the ERA platform, and found minimal differences between the two. While these results are interesting and in line with overall clinical conclusions, other genes were markedly differentially expressed compared to normal controls (Supplemental Table S3 ), which may still contribute to reduced treatment outcomes in some patients. Of note, Unlu et al. analyzed mRNA expression of endometrial receptivity markers HOXA10, HOXA11, LIF, and αvβ3 integrin in endometrium from women with submucosal and intramural noncavity-distorting fibroids before and after myomectomy [53] . They found that while there was no difference in the expression of the above markers in both groups prior to the surgery compared to control endometrium, the myomectomy increased the HOXA10 and HOXA11 endometrial gene expression in the intramural fibroid group [53] . However, the sample size was small and the intervention did not result in higher pregnancy rates. Thus, surgical intervention in subjects with noncavity-distorting intramural fibroids to enhance pregnancy rates, if not of great size causing symptoms, would be unwarranted at the molecular and clinical levels.
Decidualization is not affected in endometrial stromal fibroblast from subjects with noncavity-distorting fibroids Normal expression of established decidualization markers in MSE tissue samples and in an in vitro model of decidualization of cultured eSF from women with noncavity-distorting intramural fibroids, together with normal morphological transformation of these cells under decidualization stimuli, strongly suggests a normal response to P 4 and preserved decidualization potential in this group, despite observed gene expression changes in fibroid versus control endometrial tissue, once again supporting the prevailed clinical experience. This is in marked contrast to the P 4 -resistant phenomenon in endometriosis, which may be caused by different risk factors and/or exposures and mechanisms [54, 55] .
Putting together the experimental data on the functionality of eSF from subjects with noncavity-distorting fibroids compared to control women with no uterine pathology, key functions believed to determine that pregnancy establishment, such as endometrial receptivity and eSF decidualization, is not significantly affected. On the other hand, there is a large number of significantly dysregulated genes between the two groups in the mid-secretory phase. To reconcile these findings, we propose that apart from the known heterogeneity of human samples (herein also due in part to some missing clinical details such as precise location of intramural fibroids (although known to be noncavity distorting) and number of fibroids), it is possible that there is poor correlation between the level of gene expression and the abundance of the corresponding protein [56, 57] , which ultimately is directly linked to the function and phenotype. It should be noted that normal endometrial receptivity has not been shown to predict pregnancy outcome (term or preterm gestation, miscarriage, or pregnancy disorders associated with compromised implantation (e.g. pre-eclampsia)), and prospective studies of endometrial receptivity and these parameters are needed. Interestingly, even in the presence of a normal ERA test, women who have an abnormal endometrial microbiome (higher prevalence of nonlactobacillus profile) did not achieve pregnancy with IVF [58] , suggesting successful implantation (and perhaps pregnancy outcomes) is influenced by still to be determined factors. Furthermore, gene expression differences may reflect other processes important in normal endometrial homeostasis, communication with resident and transient immune cells, angiogenesis, and control of endometrial bleeding during the cycle and at the time of menses, in addition to nidation (Supplemental Table S4 ), and from a teleological perspective, it is possible that since uterine fibroids are so common, there may be an evolutionary adaptation such that only certain types and localizations are detrimental to fertility.
Proliferation and apoptosis
In normal human endometrium, cellular proliferation occurs in the proliferative phase, while apoptosis occurs predominantly in the late secretory and menstrual phases [59] . This study did not find striking differences in proliferation and apoptosis in eSF from women with noncavity-distorting fibroids compared to healthy women without uterine pathology at baseline. When cultured for 3 days, eSF from fibroid group demonstrated decreased proliferation in the WST-1 assay compared to controls, while the BrdU assay did not show any significant difference in proliferation between fibroid and control groups at baseline prior to decidualization (Figure 3) . The decidualization process inhibited eSF proliferation, as expected, while inducing apoptosis, which was increased in the fibroid group. In contrast, a previous study found that endometrial cells from women with symptomatic fibroids [60] demonstrated decreased apoptosis in culture, and GnRH agonists stimulated apoptosis in endometrial cells from these patients [60] . These observations suggest functional differences between eSF from subjects with different sequelae of fibroids and their location and effect on the endometrial cavity. Although the precise relevance of these findings to the clinical scenario is unclear, such diverse changes at the cellular level may contribute to the heterogeneity of the clinical outcomes in patients with noncavity-distorting fibroids.
Strengths and limitations
The greatest strength of the current study is the use of very well characterized endometrial samples from subjects with noncavitydistorting uterine fibroids and cycle phase-matched controls. However, a limitation of the study is some clinical diversity of the control subjects (although still the vast majority of controls had proven fertility or were normal volunteers without gynecologic symptoms or known gynecologic disorders), as well as that the exact number and location of the intramural fibroids in relation to the endometrial/myometrial junction were not reported, and this could account for the large number of differentially expressed genes between the groups and between different menstrual cycle phases. Another strength of the study is the use of whole tissue for gene expression analysis, which provides a snap shot of the in vivo situation, with all the participating cell types and interactions captured. This however is also a limitation of the study, because dissecting contributions of particular cell types to the observed up-and downregulation of genes and signaling pathways is precluded. For example, while endometrial stromal cells usually comprise the majority of the biopsy sample, the activation of immune pathways can be attributed not only to that cell type but also to uterine immune cell populations in the biopsy. Nevertheless, the findings presented herein support the information regarding noncavity-distorting fibroids and the endometrial processes known to date that are involved in the establishment of pregnancy, and thus will help clinicians in counseling their patients with full disclosure of the limitations of the available data. As this is the first evaluation of the endometrial transcriptome and endometrial function pertinent to endometrial receptivity in subjects with noncavity-distorting intramural fibroids, further studies will be important to validate our results, especially as other determinants of endometrial receptivity are discovered and these existing parameters are evaluated for not only pregnancy establishment but also pregnancy outcome.
In summary, our data suggest that intramural noncavitydistorting uterine fibroids do not have a detrimental effect on the endometrial transcriptome relevant to uterine receptivity and implantation potential. These molecular data correlate with the prevailing clinical observations, thus supporting the current practice of no intervention of noncavity-distorting uterine fibroids to improve conception rates.
Supplementary data
Supplementary data are available at BIOLRE online.
Supplemental Table S1 . Up-and downregulated genes in PE from subjects with noncavity-distorting endometrium (F) compared to controls (C) (cut-off P < 0.05, FC = 2).
Supplemental Table S2 . Up-and downregulated genes in ESE from subjects with noncavity-distorting endometrium (F) compared to controls (C) (cut-off P < 0.05, FC = 2).
Supplemental Table S3 . Up-and downregulated genes in MSE from subjects with noncavity-distorting endometrium (F) compared to controls (C) (cut-off P < 0.05, FC = 2).
Supplemental Table S4 .
